Biome Australia's Q1 FY25 sales revenue update

Biome Australia Limited (ASX:BIO) has reported a record quarterly sales revenue of approximately $4.25m (unaudited) for the first quarter of the financial year 2025. This represents a significant 55% increase compared to the previous corresponding period (Q1 FY24, $2.74m) and a 12% rise from the previous record quarter (Q4 FY24, $3.8m). The result surpassed the $4m target for the quarter by $250k or 6.3%. Biome's Q1 sales revenue indicates an annualised run rate of $17m, with anticipated continued growth throughout the remainder of FY25.

Biome Australia's Managing Director and Founder, Blair Vega Norfolk, on Q1 FY25 results

I am excited to share this result for Q1 FY25, another record quarter in sales revenue following our recent release of Biome's Vision 27, which outlined our growth plan and prospects over the next three years. I look forward to sharing further updates on our growth and performance in the coming periods.

Biome Australia's Q1 FY25 sales revenue summary and outlook

Biome Australia has achieved a remarkable 55% increase in sales revenue for Q1 FY25 compared to the previous year, surpassing the $4m target for the quarter. The company's Q1 sales revenue represents an annualised run rate of $17m, indicating a strong growth trajectory expected to continue throughout FY25. With the recent release of Biome's Vision 27 outlining the company's growth plan and prospects over the next three years, Biome Australia remains committed to improving health outcomes and accessibility of its innovative products. The company's focus on evidence-based live biotherapeutics and complementary medicines, supported by clinical research, underpins its dedication to enhancing health and quality of life. As Biome continues to drive growth and performance, it aims to provide further updates on its progress in the upcoming periods.